Literature DB >> 31442497

Recommended Change in the N Descriptor Proposed by the International Association for the Study of Lung Cancer: A Validation Study.

Byung Jo Park1, Tae Ho Kim1, Sumin Shin1, Hong Kwan Kim1, Yong Soo Choi1, Jhingook Kim1, Jae Ill Zo1, Young Mog Shim1, Jong Ho Cho2.   

Abstract

INTRODUCTION: The International Association for the Study of Lung Cancer recently proposed a new N descriptor by combining the location of metastatic lymph nodes (LNs), nN (single-station versus multiple-station), and absence versus presence of skip metastasis as pN1a, pN1b, pN2a1, pN2a2 and pN2b. This study aimed to evaluate the discriminatory ability and prognostic performance of the proposed N descriptor in a large independent NSCLC cohort.
METHODS: We analyzed 1228 patients who underwent major pulmonary resection for pathological N1 or N2 NSCLC between 2004 and 2014. Survival analysis using the Cox proportional hazard model was performed to assess the prognostic significance of the N descriptor.
RESULTS: From 2004 to 2014, a total of 7437 patients were operated on for NSCLC. Patients pathologically confirmed as having N1 (n = 732) or N2 (n = 496) disease after surgery were included. The median total number of dissected LNs was 24 (range 10-83), and the median number of involved LNs was 2 (range 1-40). The 5-year overall survival rates were 62.6%, 57.0%, 64.7%, 48.4%, and 42.8% for stages N1a, N1b, N2a1, N2a2, and N2b, respectively. Analysis of overall and recurrence-free survival revealed that N2a1 is not sufficiently distinguished from N1a and N1b. In terms of overall survival, N1b is not sufficiently distinguished from N2a2.
CONCLUSION: On the basis of the N descriptor proposed by the International Association for the Study of Lung Cancer, some of the prognostic implications of the five groups overlapped. It would be better to classify similar prognostic groups into three or four groups to divide the group. A large-scale prospective study is needed to validate these N descriptors.
Copyright © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  LN station number; N stage; Non–small cell lung cancer; N descriptor

Mesh:

Year:  2019        PMID: 31442497     DOI: 10.1016/j.jtho.2019.07.034

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  7 in total

1.  Does anatomical location-based metastatic lymph node density affect prognosis in lung cancer patients?

Authors:  Yunus Aksoy; Necati Çıtak; Çiğdem Obuz; Muzaffer Metin; Adnan Sayar
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-10-04

2.  Skip metastasis in mediastinal lymph node is a favorable prognostic factor in N2 lung cancer patients: a meta-analysis.

Authors:  Zihuai Wang; Jiahan Cheng; Wenyu Huang; Diou Cheng; Yilin Liu; Qiang Pu; Nathan E Reticker-Flynn; Lunxu Liu
Journal:  Ann Transl Med       Date:  2021-02

3.  Validation of the Proposed cN2 Subclassification in the Eighth Edition of the IASLC Staging System: A Prospective Phase II Multicenter Study.

Authors:  Jiro Abe; Yuji Matsumura; Satoshi Shiono; Masaya Aoki; Masami Sato; Hiroyuki Oura; Hirohisa Kato; Muneo Minowa; Hiroyuki Oizumi; Motoyasu Sagawa; Akira Sakurada; Yoshinori Okada
Journal:  JTO Clin Res Rep       Date:  2020-02-27

4.  Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study.

Authors:  K Sinn; B Mosleh; A Steindl; S Zoechbauer-Mueller; K Dieckmann; J Widder; E Steiner; W Klepetko; K Hoetzenecker; V Laszlo; B Doeme; T Klikovits; M A Hoda
Journal:  ESMO Open       Date:  2022-04-06

5.  [Prognostic Factors of N2 Stage Non-small Cell Lung Cancer after Surgery].

Authors:  Zhenyu Yang; Shiyou Wei; Liang Xia; Lunxu Liu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-01-20

6.  Survival Analysis in Single N2 Station Lung Adenocarcinoma: The Prognostic Role of Involved Lymph Nodes and Adjuvant Therapy.

Authors:  Marco Chiappetta; Filippo Lococo; Giovanni Leuzzi; Isabella Sperduti; Emilio Bria; Leonardo Petracca Ciavarella; Felice Mucilli; Pier Luigi Filosso; Giovannibattista Ratto; Lorenzo Spaggiari; Francesco Facciolo; Stefano Margaritora
Journal:  Cancers (Basel)       Date:  2021-03-16       Impact factor: 6.639

7.  New PET/CT criterion for predicting lymph node metastasis in resectable advanced (stage IB-III) lung cancer: The standard uptake values ratio of ipsilateral/contralateral hilar nodes.

Authors:  Komei Kameyama; Kazuhiro Imai; Koichi Ishiyama; Shinogu Takashima; Shoji Kuriyama; Maiko Atari; Yoshiaki Ishii; Akihito Kobayashi; Shugo Takahashi; Mirai Kobayashi; Yuzu Harata; Yusuke Sato; Satoru Motoyama; Manabu Hashimoto; Kyoko Nomura; Yoshihiro Minamiya
Journal:  Thorac Cancer       Date:  2022-01-20       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.